Background: Hypertension affects almost all chronic kidney disease patients and is related to poor outcomes. Sodium intake is closely related to blood pressure (BP) levels in this population and decreasing its intake consistently improves the BP control particularly in short-term controlled trials. However, most patients struggle in following a controlled diet on sodium according to the guidelines recommendation due to several factors and barriers discussed in this article. Summary: This review article summarizes the current knowledge related to the associations between sodium consumption, BP, and the risk of cardiovascular disease and chronic kidney disease (CKD); it also provides recommendations of how to achieve sodium intake lowering. Key Messages: Evidences support the benefits in decreasing sodium intake on markers of cardiovascular and renal outcomes in CKD. Trials had shorter follow-up and to maintain long-term sodium intake control is a major challenge. Larger studies with longer follow-up looking at hard endpoints will be important to drive future recommendations.

Keywords:
Chronic kidney disease, Sodium intake, Salt intake, Blood pressure
1.
Institute of Medicine: Dietary Reference Intakes for Water, Potassium, Sodium, Chloride, and Sulfate. National Academies Press, Washington, 2005, p 640.
2.
Zhao D, Qi Y, Zheng Z, Wang Y, Zhang XY, Li HJ, et al: Dietary factors associated with hypertension. Nat Rev Cardiol 2011; 8: 456–465.
3.
He FJ, MacGregor GA: Reducing population salt intake worldwide: from evidence to implementation. Prog Cardiovasc Dis 2010; 52: 363–382.
4.
Mills KT, Bundy JD, Kelly TN, Reed JE, Kearney PM, Reynolds K, et al: Global disparities of hypertension prevalence and control: a systematic analysis of population-based studies from 90 countries. Circulation 2016; 134: 441–450.
5.
Mozaffarian D, Fahimi S, Singh GM, Micha R, Khatibzadeh S, Engell RE, et al: Global sodium consumption and death from cardiovascular causes. N Engl J Med 2014; 371: 624–634.
6.
O'Brien E, Pickering T, Asmar R, Myers M, Parati G, Staessen J, et al: Working Group on Blood Pressure Monitoring of the European Society of Hypertension International Protocol for validation of blood pressure measuring devices in adults. Blood Press Monit 2002; 7: 3–17.
7.
World Health Organization: WHO | Sodium Intake for Adults and Children. Geneva, World Health Organization, 2012, p 56.
8.
Powles J, Fahimi S, Micha R, Khatibzadeh S, Shi P, Ezzati M, et al: Global, regional and national sodium intakes in 1990 and 2010: a systematic analysis of 24 h urinary sodium excretion and dietary surveys worldwide. BMJ Open 2013; 3:e003733.
9.
McMahon EJ, Bauer JD, Hawley CM, Isbel NM, Stowasser M, Johnson DW, et al: The effect of lowering salt intake on ambulatory blood pressure to reduce cardiovascular risk in chronic kidney disease (LowSALT CKD study): protocol of a randomized trial. BMC Nephrol 2012; 13: 137.
10.
Essig M, Escoubet B, de Zuttere D, Blanchet F, Arnoult F, Dupuis E, et al: Cardiovascular remodelling and extracellular fluid excess in early stages of chronic kidney disease. Nephrol Dial Transplant 2008; 23: 239–248.
11.
Sacks FM, Svetkey LP, Vollmer WM, Appel LJ, Bray GA, Harsha D, et al: Effects on blood pressure of reduced dietary sodium and the Dietary Approaches to Stop Hypertension (DASH) diet. DASH-Sodium Collaborative Research Group. N Engl J Med 2001; 344: 3–10.
12.
Ritz E, Dikow R, Morath C, Schwenger V: Salt – a potential ‘uremic toxin’? Blood Purif 2006; 24: 63–66.
13.
Verhave JC, Hillege HL, Burgerhof JG, Janssen WM, Gansevoort RT, Navis GJ, et al: Sodium intake affects urinary albumin excretion especially in overweight subjects. J Intern Med 2004; 256: 324–330.
14.
De Brito-Ashurst I, Perry L, Sanders TA, Thomas JE, Dobbie H, Varagunam M, et al: The role of salt intake and salt sensitivity in the management of hypertension in South Asian people with chronic kidney disease: a randomised controlled trial. Heart 2013; 99: 1256–1260.
15.
Anavekar NS, Gans DJ, Berl T, Rohde RD, Cooper W, Bhaumik A, et al: Predictors of cardiovascular events in patients with type 2 diabetic nephropathy and hypertension: a case for albuminuria. Kidney Int Suppl 2004; 66:S50–S55.
16.
Borch-Johnsen K, Kreiner S: Proteinuria: value as predictor of cardiovascular mortality in insulin dependent diabetes mellitus. Br Med J (Clin Res Ed) 1987; 294: 1651–1654.
17.
Titze J, Shakibaei M, Schafflhuber M, Schulze-Tanzil G, Porst M, Schwind KH, et al: Glycosaminoglycan polymerization may enable osmotically inactive Na+ storage in the skin. Am J Physiol Heart Circ Physiol 2004; 287:H203–H208.
18.
Guyton AC: Dominant role of the kidneys and accessory role of whole-body autoregulation in the pathogenesis of hypertension. Am J Hypertens 1989; 2: 575–585.
19.
Kimura G, Dohi Y, Fukuda M: Salt sensitivity and circadian rhythm of blood pressure: the keys to connect CKD with cardiovasucular events. Hypertens Res 2010; 33: 515–520.
20.
Koomans HA, Roos JC, Boer P, Geyskes GG, Mees EJ: Salt sensitivity of blood pressure in chronic renal failure. Evidence for renal control of body fluid distribution in man. Hypertension 1982; 4: 190–197.
21.
Yu HC, Burrell LM, Black MJ, Wu LL, Dilley RJ, Cooper ME, et al: Salt induces myocardial and renal fibrosis in normotensive and hypertensive rats. Circulation 1998; 98: 2621–2628.
22.
Rocha R, Funder JW: The pathophysiology of aldosterone in the cardiovascular system. Ann N Y Acad Sci 2002; 970: 89–100.
23.
Joffe HV, Adler GK: Effect of aldosterone and mineralocorticoid receptor blockade on vascular inflammation. Heart Fail Rev 2005; 10: 31–37.
24.
Ozkahya M, Ok E, Cirit M, Aydin S, Akçiçek F, Başçi A, et al: Regression of left ventricular hypertrophy in haemodialysis patients by ultrafiltration and reduced salt intake without antihypertensive drugs. Nephrol Dial Transplant 1998; 13: 1489–1493.
25.
Ozkahya M, Toz H, Qzerkan F, Duman S, Ok E, Basci A, et al: Impact of volume control on left ventricular hypertrophy in dialysis patients. J Nephrol 2002; 15: 655–660.
26.
Messerli FH, Schmieder RE, Weir MR: Salt. A perpetrator of hypertensive target organ disease? Arch Intern Med 1997; 157: 2449–2452.
27.
du Cailar G, Mimran A, Fesler P, Ribstein J, Blacher J, Safar ME: Dietary sodium and pulse pressure in normotensive and essential hypertensive subjects. J Hypertens 2004; 22: 697–703.
28.
Fraser SD, Roderick PJ, McIntyre NJ, Harris S, McIntyre CW, Fluck RJ, et al: Suboptimal blood pressure control in chronic kidney disease stage 3: baseline data from a cohort study in primary care. BMC Fam Pract 2013; 14: 88.
29.
Kalaitzidis R, Li S, Wang C, Chen SC, McCullough PA, Bakris GL: Hypertension in early-stage kidney disease: an update from the Kidney Early Evaluation Program (KEEP). Am J Kidney Dis 2009; 53(4 suppl 4):S22–S31.
30.
Kuznik A, Mardekian J, Tarasenko L: Evaluation of cardiovascular disease burden and therapeutic goal attainment in US adults with chronic kidney disease: an analysis of national health and nutritional examination survey data, 2001–2010. BMC Nephrol 2013; 14: 132.
31.
Ogura M, Kimura A, Takane K, Nakao M, Hamaguchi A, Terawaki H, et al: Estimation of salt intake from spot urine samples in patients with chronic kidney disease. BMC Nephrol 2012; 13: 36.
32.
Nerbass FB, Pecoits-Filho R, McIntyre NJ, McIntyre CW, Willingham FC, Taal MW: Demographic associations of high estimated sodium intake and frequency of consumption of high-sodium foods in people with chronic kidney disease stage 3 in England. J Ren Nutr 2014; 24: 236–242.
33.
Nerbass FB, Hallvass AE, Taal MW, Pecoits-Filho R: Formula to detect high sodium excretion from spot urine in chronic kidney disease patients. J Bras Nefrol 2017; 39: 23–28.
34.
Yu W, Luying S, Haiyan W, Xiaomei L: Importance and benefits of dietary sodium restriction in the management of chronic kidney disease patients: experience from a single Chinese center. Int Urol Nephrol 2012; 44: 549–556.
35.
Meuleman Y, Hoekstra T, Dekker FW, van der Boog PJ, van Dijk S; ESMO Study Group: Perceived sodium reduction barriers among patients with chronic kidney disease: which barriers are important and which patients experience barriers? Int J Behav Med 2017, Epub ahead of print.
36.
Boudville N, Ward S, Benaroia M, House AA: Increased sodium intake correlates with greater use of antihypertensive agents by subjects with chronic kidney disease. Am J Hypertens 2005; 18: 1300–1305.
37.
Elliott P, Brown I: Sodium Intakes Around the World. Geneva, World Health Organization, 2007.
38.
Jain M, Howe GR, Rohan T: Dietary assessment in epidemiology: comparison on food frequency and a diet history questionnaire with a 7-day food record. Am J Epidemiol 1996; 143: 953–960.
39.
Bingham SA: Limitations of the various methods for collecting dietary intake data. Ann Nutr Metab 1991; 35: 117–127.
40.
Nerbass FB, Pecoits-Filho R, McIntyre NJ, McIntyre CW, Taal MW: Development of a formula for estimation of sodium intake from spot urine in people with chronic kidney disease. Nephron Clin Pract 2014; 128: 61–66.
41.
Dougher CE, Rifkin DE, Anderson CA, Smits G, Persky MS, Block GA, et al: Spot urine sodium measurements do not accurately estimate dietary sodium intake in chronic kidney disease. Am J Clin Nutr 2016; 104: 298–305.
42.
de Brito-Ashurst I, Perry L, Sanders TA, Thomas JE, Yaqoob MM, Dobbie H: Barriers and facilitators of dietary sodium restriction amongst Bangladeshi chronic kidney disease patients. J Hum Nutr Diet 2011; 24: 86–95.
43.
Meuleman Y, ten Brinke L, Kwakernaak AJ, Vogt L, Rotmans JI, Bos WJ, et al: Perceived barriers and support strategies for reducing sodium intake in patients with chronic kidney disease: a Qualitative study. Int J Behav Med 2015; 22: 530–539.
44.
McMahon EJ, Campbell KL, Bauer JD, Mudge DW: Altered dietary salt intake for people with chronic kidney disease. Cochrane database Syst Rev 2015; 2:CD010070.
45.
Saran R, Padilla RL, Gillespie BW, Heung M, Hummel SL, Derebail VK, et al: A randomized crossover trial of dietary sodium restriction in stage 3-4 CKD. Clin J Am Soc Nephrol 2017; 12: 399–407.
46.
Meuleman Y, Hoekstra T, Dekker FW, Navis G, Vogt L, van der Boog PJM, et al: Sodium restriction in patients with CKD: a randomized controlled trial of self-management support. Am J Kidney Dis 2017; 69: 576–586.
47.
Vegter S, Perna A, Postma MJ, Navis G, Remuzzi G, Ruggenenti P: Sodium intake, ACE inhibition, and progression to ESRD. J Am Soc Nephrol 2012; 23: 165–173.
48.
Lambers Heerspink HJ, Holtkamp FA, Parving HH, Navis GJ, Lewis JB, Ritz E, et al: Moderation of dietary sodium potentiates the renal and cardiovascular protective effects of angiotensin receptor blockers. Kidney Int 2012; 82: 330–337.
49.
Mills KT, Chen J, Yang W, Appel LJ, Kusek JW, Alper A, et al: Sodium excretion and the risk of cardiovascular disease in patients with chronic kidney disease. JAMA 2016; 315: 2200–2210.
50.
He J, Mills KT, Appel LJ, Yang W, Chen J, Lee BT, et al: Urinary sodium and potassium excretion and CKD progression. J Am Soc Nephrol 2016; 27: 1202–1212.
51.
National Kidney Foundation: KDIGO clinical practice guideline for the management of blood pressure in chronic kidney disease. Kidney Int 2012; 2(suppl):337–414.
52.
Cuppari L, Nerbass FB, Avesani CM, Kamimura MA: A practical approach to dietary interventions for nondialysis-dependent CKD patients: the experience of a reference nephrology center in Brazil. BMC Nephrol 2016; 17: 85.
53.
Ameh OI, Cilliers L, Okpechi IG: A practical approach to the nutritional management of chronic kidney disease patients in Cape Town, South Africa. BMC Nephrol 2016; 17: 68.
54.
Iseki K, Yamagata K: A practical approach of salt and protein restriction for CKD patients in Japan. BMC Nephrol 2016; 17: 87.
55.
D'Alessandro C, Piccoli GB, Calella P, Brunori G, Pasticci F, Egidi MF, et al: “Dietaly”: practical issues for the nutritional management of CKD patients in Italy. BMC Nephrol 2016; 17: 102.
56.
Konishi Y, Morikawa T, Yasu T, Teramoto K, Okada N, Yoshioka K, et al: Blunted response of the Renin-Angiotensin system and nitric oxide synthesis related to sodium sensitivity in immunoglobulin a nephropathy. Hypertens Res 2004; 27: 7–13.
57.
Krikken JA, Waanders F, Dallinga-Thie GM, Dikkeschei LD, Vogt L, Navis GJ, et al: Antiproteinuric therapy decreases LDL-cholesterol as well as HDL-cholesterol in non-diabetic proteinuric patients: relationships with cholesteryl ester transfer protein mass and adiponectin. Expert Opin Ther Targets 2009; 13: 497–504.
58.
Kwakernaak AJ, Lambert G, Slagman MC, Waanders F, Laverman GD, Petrides F, et al: Proprotein convertase subtilisin-kexin type 9 is elevated in proteinuric subjects: relationship with lipoprotein response to antiproteinuric treatment. Atherosclerosis 2013; 226: 459–465.
59.
McMahon EJ, Bauer JD, Hawley CM, Isbel NM, Stowasser M, Johnson DW, et al: A randomized trial of dietary sodium restriction in CKD. J Am Soc Nephrol 2013; 24: 2096–2103.
© 2018 S. Karger AG, Basel
2018
Copyright / Drug Dosage / Disclaimer
Copyright: All rights reserved. No part of this publication may be translated into other languages, reproduced or utilized in any form or by any means, electronic or mechanical, including photocopying, recording, microcopying, or by any information storage and retrieval system, without permission in writing from the publisher.
Drug Dosage: The authors and the publisher have exerted every effort to ensure that drug selection and dosage set forth in this text are in accord with current recommendations and practice at the time of publication. However, in view of ongoing research, changes in government regulations, and the constant flow of information relating to drug therapy and drug reactions, the reader is urged to check the package insert for each drug for any changes in indications and dosage and for added warnings and precautions. This is particularly important when the recommended agent is a new and/or infrequently employed drug.
Disclaimer: The statements, opinions and data contained in this publication are solely those of the individual authors and contributors and not of the publishers and the editor(s). The appearance of advertisements or/and product references in the publication is not a warranty, endorsement, or approval of the products or services advertised or of their effectiveness, quality or safety. The publisher and the editor(s) disclaim responsibility for any injury to persons or property resulting from any ideas, methods, instructions or products referred to in the content or advertisements.
You do not currently have access to this content.